oncnursingnews2d
Adding Lenvatinib/Pembrolizumab to TACE Extends PFS in Unresectable Liver Cancer
The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...
oncnursingnews2d
Investigational Nasal Spray May Improve Symptoms in Cancer Cachexia
Findings from an exploratory 2a study showed improvements in patients with cancer cachexia with PH284 compared with placebo.
oncnursingnews3d
Drug Toxicity May Drive Early Niraparib Discontinuation in Ovarian Cancer
Improved education on drug toxicity management, especially within the first 90 days of treatment and regarding individualized ...
oncnursingnews3d
Sotorasib Plus Panitumumab Receives FDA Approval for KRAS G12C–Mutated Colorectal Cancer
The FDA has approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) ...
oncnursingnews3d
FDA Approves Acalabrutinib-Based Regimen for Previously Treated MCL
The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle ...
oncnursingnews6d
Sasanlimab/BCG Combo Shows Promise in Treating High-Risk NMIBC
Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk ...
oncnursingnews3dOpinion
Opinion: Subcutaneous Nivolumab Offers an Effective Alternative to Intravenous Administration
Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...
oncnursingnews3d
FDA Approves Datopotamab Deruxtecan for Advanced Breast Cancer
Datopotamab deruxtecan-dlnk received approval from the FDA for previously treated unresectable or metastatic, HR-positive, HER2-negative breast cancer. The FDA granted approval to datopotamab ...